SNFGE SNFGE
 
Thématique :
- MICI
Originalité :
Intermédiaire
Solidité :
Très solide
Doit faire évoluer notre pratique :
Immédiatement
 
 
Nom du veilleur :
Docteur Patrick FAURE
Coup de coeur :
 
 
Gut
  2017/04  
 
  2017 Apr;66(4):588-596.  
  doi: 10.1136/gutjnl-2015-310151.  
 
  Validation of the Inflammatory Bowel Disease Disability Index in a population-based cohort  
 
  Gower-Rousseau C, Sarter H, Savoye G, Tavernier N, Fumery M, Sandborn WJ, Feagan BG, Duhamel A, Guillon-Dellac N, Colombel JF, Peyrin-Biroulet L; and the International Programme to Develop New Indexes for Crohn's Disease (IPNIC) group; International Programme to Develop New Indexes for Crohn's Disease (IPNIC) group.  
  https://www.ncbi.nlm.nih.gov/pubmed/26646934  
 
 

Abstract

BACKGROUND:

IBDs are chronic destructive disorders that negatively affect the functional status of patients. Recently, the Inflammatory Bowel Disease Disability Index (IBD-DI) was developed according to standard WHO processes. The aims of the current study were to validate the IBD-DI in an independent patient cohort, to develop an index-specific scoring system and to describe the disability status of a well-defined population-based cohort of French patients with IBD.

METHODS:

From February 2012 to March 2014, the IBD-DI questionnaire was administered to a random sample of adult patients with an established diagnosis of IBD issued from a French population-based registry. The IBD-DI consists of 28 items that evaluate the four domains of body functions, activity participation, body structures and environmental factors. Validation included item reduction and data structure, construct validity, internal consistency, interobserver and intraobserver reliability evaluations.

RESULTS:

150 patients with Crohn's disease (CD) and 50 patients with UC completed the IBD-DI validation phase. The intraclass correlation coefficient for interobserver reliability was 0.91 and 0.54 for intraobserver reliability. Cronbach's α of internal consistency was 0.86. IBD-DI scores varied from 0 to 100 with a mean of 35.3 (Q1=19.6; Q3=51.8). IBD-DI scores were highly correlated with Inflammatory Bowel Disease Questionnaire (-0.82; p<0.001) and SF-36 (-0.61; p<0.05) scores. Female gender (p<0.001), clinical disease activity (p<0.0001) and disease duration (p=0.02) were associated with higher IBD-DI scores.

CONCLUSIONS:

The IBD-DI has been validated for use in clinical trials and epidemiological studies. The IBD-DI showed high internal consistency, interobserver reliability and construct validity, and a moderate intraobserver reliability. It comprises 14 questions and ranges from 0 to 100. The mean IBD-DI score was 35.3 and was associated with gender, clinical disease activity and disease duration. Further research is needed to confirm the structural validity and to assess the responsiveness of IBD-DI.

TRIAL REGISTRATION NUMBER:

2011-A00877-34.

 

 
Question posée
 
Le concept de quantification du handicap a été établi pour l'évaluation de nombreuses maladies chroniques. Cependant, il n’existait pas d’index validé dans les MICI alors que cette pathologie peut affecter négativement les patients sur le plan physique, psychologique, familial et social. L’objectif de ce groupe de travail était de valider un index d’handicape (IBD-DI) dans une cohorte en population.
 
Question posée
 
L’index d'incapacité (IBD-DI) a été développé selon la classification OMS. La qualité des données générées par l'IBD-DI était excellente. Il existait une bonne fiabilité et une bonne corrélation entre IBD-DI, le SF-36 et l’IBDQ, Le score IBD-DI variait de 0 à 91 (score maximal possible de 100) et la moyenne de l'IBD-DI était de 35,3 (± 20% en SD). Les facteurs de risque associés pour des scores élevés d’handicape (I’IBD-DI) étaient le sexe féminin, la longue durée de la maladie et une activité clinique élevée de la maladie.
 
Commentaires

-

 
www.snfge.org